EYEG - アイゲ―ト・ファ―マシュ―ティカルズ (Eyegate Pharmaceuticals Inc.) アイゲ―ト・ファ―マシュ―ティカルズ

 EYEGのチャート


 EYEGの企業情報

symbol EYEG
会社名 Eyegate Pharmaceuticals Inc. (アイゲ―ト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アイ・ゲート・ファーマシューティク(Eyegate Pharmaceuticals Inc.)は臨床段階の特殊医薬品会社。同社は、眼の疾患を治療するための薬物送達システムと治療法を開発・商業化する。臨床試験における同社の製品EGP-437は、その薬物送達システム、EyeGate II輸送システムを通じて眼組織に送達される再定式局所的に活性なコルチコステロイド、デキサメタゾン、リン酸が組み込まれている。   アイゲ―ト・ファ―マシュ―ティカルズは米国の眼科向け医薬品企業。臨床段階で、目の疾患に対する治療薬と薬物送達システムの開発、商業化に従事する。主に虹彩や毛様体に炎症を起こすブドウ膜炎や黄斑浮腫の治療薬「EGP-437」を開発、活性副腎皮質ステロイド(リン酸デキサメタゾン)を含み局所療法として使用される。本社はマサチュ―セッツ州。   EyeGate Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate's lead product, Ocular Bandage Gel ('OBG'), is based on a modified form of the natural polymer hyaluronic acid. The objective of OBG is to protect the ocular surface in order for the body to re-epithelialize the cornea and improve ocular surface integrity. The product is applied as a clear topical gel, to the damaged ocular surface, and possesses unique properties that help hydrate and protect the ocular surface to allow for wound healing. EyeGate is in clinical evaluation for two different patient populations: (1) patients undergoing photorefractive keratectomy ('PRK') surgery to demonstrate corneal wound repair after refractive surgery; and (2) patients with punctate epitheliopathies ('PE') as a result of dry eye to promote reduction of PEs.
本社所在地 271 Waverley Oaks Road Suite 108 Waltham MA 02452 USA
代表者氏名 Paul G. Chaney ポール・G・チェニー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 781-788-9043
設立年月日 38322
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数
url www.eyegatepharma.com
nasdaq_url https://www.nasdaq.com/symbol/eyeg
adr_tso
EBITDA EBITDA(百万ドル) -13.46404
終値(lastsale) 0.388
時価総額(marketcap) 16854382.44
時価総額 時価総額(百万ドル) 18.19665
売上高 売上高(百万ドル) 1.41272
企業価値(EV) 企業価値(EV)(百万ドル) 5.60164
当期純利益 当期純利益(百万ドル) -12.13099
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Eyegate Pharmaceuticals Inc revenues increased from $333K to $1.3M. Net loss decreased 17% to $5.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in SGA decrease of 55% to $184K (expense) General and Administrative Expense - Bal decrease of 6% to $2M (expense).

 EYEGのテクニカル分析


 EYEGのニュース

   EyeGate is Now Kiora Pharmaceuticals; Provides Update on Companys Sharpened Clinical Development Strategy  2021/11/08 12:30:00 Intrado Digital Media
SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (Kiora or the Company) is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG). Kiora will trade on the Nasdaq Capital Market under the ticker symbol "KPRX" and CUSIP number 49721T101. The new brand reflects the Companys aim to not only treat common eye conditions, but to develop a revolutionary small molecule therapy that has the potential to restore vision loss for a rare, inherited degenerative retinal disease, Retinitis Pigmentosa. The Companys newly revamped clinical development strategy is available in the Investors section of the Companys new website at www.kiorapharma.com .
   EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) Offers Great Upside  2021/11/06 18:00:00 Stocks Register
EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) shares, rose in value on Friday, 11/05/21, with the stock price down by -1.52% to the previous days close as strong demand from buyers drove the stock to $1.95. Actively observing the price movement in the last trading, the stock closed the session at $1.98, falling within a range of $1.92 EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) Offers Great Upside Read More »
   EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) Could Slash -689.47% Soon  2021/10/30 18:00:00 Stocks Register
EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) price on Friday, October 29, rose 0.53% above its previous days close as an upside momentum from buyers pushed the stocks value to $1.90. A look at the stocks price movement, the close in the last trading session was $1.89, moving within a range at $1.86 and $1.935. The beta value EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) Could Slash -689.47% Soon Read More »
   Can EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) Stock Be A Good Mid-Term Investment?  2021/10/27 11:30:00 Stocks Register
EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) price closed higher on Tuesday, October 26, jumping 4.10% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy
   stocks Performances and Technicals to scrutinize: Northern Dynasty Minerals Ltd. (AMEX:NAK 0.46%), EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG 2.40%)  2021/10/22 00:17:21 Stock Equity
There are two main reasons why moving averages are useful in forex trading: Ø moving averages help traders define trend Ø recognize changes in trend. Now well have a look The post stocks Performances and Technicals to scrutinize: Northern Dynasty Minerals Ltd. (AMEX:NAK 0.46%), EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG 2.40%) appeared first on Stocks Equity .
   EyeGate is Now Kiora Pharmaceuticals; Provides Update on Companys Sharpened Clinical Development Strategy  2021/11/08 12:30:00 Intrado Digital Media
SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (Kiora or the Company) is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG). Kiora will trade on the Nasdaq Capital Market under the ticker symbol "KPRX" and CUSIP number 49721T101. The new brand reflects the Companys aim to not only treat common eye conditions, but to develop a revolutionary small molecule therapy that has the potential to restore vision loss for a rare, inherited degenerative retinal disease, Retinitis Pigmentosa. The Companys newly revamped clinical development strategy is available in the Investors section of the Companys new website at www.kiorapharma.com .
   EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) Offers Great Upside  2021/11/06 18:00:00 Stocks Register
EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) shares, rose in value on Friday, 11/05/21, with the stock price down by -1.52% to the previous days close as strong demand from buyers drove the stock to $1.95. Actively observing the price movement in the last trading, the stock closed the session at $1.98, falling within a range of $1.92 EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) Offers Great Upside Read More »
   EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) Could Slash -689.47% Soon  2021/10/30 18:00:00 Stocks Register
EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) price on Friday, October 29, rose 0.53% above its previous days close as an upside momentum from buyers pushed the stocks value to $1.90. A look at the stocks price movement, the close in the last trading session was $1.89, moving within a range at $1.86 and $1.935. The beta value EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) Could Slash -689.47% Soon Read More »
   Can EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) Stock Be A Good Mid-Term Investment?  2021/10/27 11:30:00 Stocks Register
EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) price closed higher on Tuesday, October 26, jumping 4.10% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy
   stocks Performances and Technicals to scrutinize: Northern Dynasty Minerals Ltd. (AMEX:NAK 0.46%), EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG 2.40%)  2021/10/22 00:17:21 Stock Equity
There are two main reasons why moving averages are useful in forex trading: Ø moving averages help traders define trend Ø recognize changes in trend. Now well have a look The post stocks Performances and Technicals to scrutinize: Northern Dynasty Minerals Ltd. (AMEX:NAK 0.46%), EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG 2.40%) appeared first on Stocks Equity .
   Where Do Hedge Funds Stand On Eyegate Pharmaceuticals, Inc. (EYEG)?  2021/06/30 13:56:26 Insider Monkey
   Eyegate Pharmaceuticals reports Q1 results  2021/05/12 20:44:04 Seeking Alpha
   EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update  2021/05/12 20:15:00 GlobeNewswire
- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21-
   Analysts Are Pretty Bullish EyeGate Pharmaceuticals (NASDAQ:EYEG)  2021/05/12 10:07:00 Stock Market Daily
Earnings results for EyeGate Pharmaceuticals , Analyst Opinion on EyeGate Pharmaceuticals , Earnings and Valuation of (NASDAQ:EYEG), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Analysts Are Pretty Bullish EyeGate Pharmaceuticals (NASDAQ:EYEG) appeared first on .

 関連キーワード  (医薬品 米国株 アイゲ―ト・ファ―マシュ―ティカルズ EYEG Eyegate Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)